These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Relationship between the structural conformation of monoclonal antibody layers and antigen binding capacity. Xu H; Zhao X; Lu JR; Williams DE Biomacromolecules; 2007 Aug; 8(8):2422-8. PubMed ID: 17616226 [TBL] [Abstract][Full Text] [Related]
12. Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo. Devanaboyina SC; Li P; LaGory EL; Poon-Andersen C; Cook KD; Soto M; Wang Z; Dang K; Uyeda C; Case RB; Thomas VA; Primack R; Ponce M; Di M; Ouyang B; Kaner J; Lam SK; Mostafavi M MAbs; 2024; 16(1):2383013. PubMed ID: 39051531 [TBL] [Abstract][Full Text] [Related]
13. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033 [TBL] [Abstract][Full Text] [Related]
14. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. Yuan D; Rode F; Cao Y Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258 [TBL] [Abstract][Full Text] [Related]
15. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. Sheridan D; Yu ZX; Zhang Y; Patel R; Sun F; Lasaro MA; Bouchard K; Andrien B; Marozsan A; Wang Y; Tamburini P PLoS One; 2018; 13(4):e0195909. PubMed ID: 29649283 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128 [TBL] [Abstract][Full Text] [Related]
17. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Gurbaxani B; Dostalek M; Gardner I Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469 [TBL] [Abstract][Full Text] [Related]